Neimeth International Pharmaceuticals Plc manufactures and markets pharmaceutical, animal health, and general healthcare products in Nigeria and Ghana.
Price History & Performance
|Historical stock prices|
|Current Share Price||₦1.76|
|52 Week High||₦1.48|
|52 Week Low||₦2.91|
|1 Month Change||0.57%|
|3 Month Change||0.57%|
|1 Year Change||-2.22%|
|3 Year Change||258.52%|
|5 Year Change||147.63%|
|Change since IPO||-14.02%|
Recent News & Updates
|NEIMETH||NG Pharmaceuticals||NG Market|
Return vs Industry: NEIMETH underperformed the NG Pharmaceuticals industry which returned 39.5% over the past year.
Return vs Market: NEIMETH underperformed the NG Market which returned 40.4% over the past year.
Stable Share Price: NEIMETH is more volatile than 75% of NG stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: NEIMETH's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of NG stocks.
About the Company
|1957||166||Pharm. Matthew Azoji||https://www.neimethplc.com.ng|
Neimeth International Pharmaceuticals Plc manufactures and markets pharmaceutical, animal health, and general healthcare products in Nigeria and Ghana. It operates through Pharmaceuticals and Animal Health segments. The company provides anti-hypertensive, blood disorders, and other products for internal organs, cardiovascular system, and chronic illnesses diseases; anti-malarial, antibiotics, and antifungals products; and multivitamins for pregnant and lactating mothers, intermittent preventive therapy (IPT) for malaria in pregnancy, and antimalarial and deworming agents.
Neimeth International Pharmaceuticals Fundamentals Summary
|NEIMETH fundamental statistics|
Is NEIMETH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NEIMETH income statement (TTM)|
|Cost of Revenue||₦1.51b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.031|
|Net Profit Margin||2.11%|
How did NEIMETH perform over the long term?See historical performance and comparison
3.7%Current Dividend Yield
Is Neimeth International Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: NEIMETH (NGN1.76) is trading above our estimate of fair value (NGN0.25)
Significantly Below Fair Value: NEIMETH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: NEIMETH is poor value based on its PE Ratio (56x) compared to the African Pharmaceuticals industry average (9.7x).
PE vs Market: NEIMETH is poor value based on its PE Ratio (56x) compared to the NG market (7.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NEIMETH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NEIMETH is overvalued based on its PB Ratio (2.7x) compared to the XF Pharmaceuticals industry average (1.5x).
How is Neimeth International Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Neimeth International Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Neimeth International Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NEIMETH has high quality earnings.
Growing Profit Margin: NEIMETH's current net profit margins (2.1%) are lower than last year (14.4%).
Past Earnings Growth Analysis
Earnings Trend: NEIMETH has become profitable over the past 5 years, growing earnings by 52.4% per year.
Accelerating Growth: NEIMETH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NEIMETH had negative earnings growth (-86%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10%).
Return on Equity
High ROE: NEIMETH's Return on Equity (4.9%) is considered low.
How is Neimeth International Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: NEIMETH's short term assets (NGN5.1B) exceed its short term liabilities (NGN2.3B).
Long Term Liabilities: NEIMETH's short term assets (NGN5.1B) exceed its long term liabilities (NGN2.9B).
Debt to Equity History and Analysis
Debt Level: NEIMETH's debt to equity ratio (356%) is considered high.
Reducing Debt: NEIMETH's debt to equity ratio has increased from 60.2% to 356% over the past 5 years.
Debt Coverage: NEIMETH's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: NEIMETH's interest payments on its debt are well covered by EBIT (8.4x coverage).
What is Neimeth International Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: NEIMETH's dividend (3.69%) is higher than the bottom 25% of dividend payers in the NG market (3.28%).
High Dividend: NEIMETH's dividend (3.69%) is low compared to the top 25% of dividend payers in the NG market (7.27%).
Stability and Growth of Payments
Stable Dividend: NEIMETH's dividend payments have been volatile in the past 10 years.
Growing Dividend: NEIMETH's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (206.9%), NEIMETH's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pharm. Matthew Azoji
Mr. Pharm. Matthew O. Azoji is Managing Director, CEO and Member of Board at Neimeth International Pharmace since February 2019. Pharm. Azoji graduated from the Obafemi Awolowo University, Ile-Ife, Osun St...
Experienced Management: NEIMETH's management team is considered experienced (2.8 years average tenure).
Experienced Board: NEIMETH's board of directors are considered experienced (9.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Neimeth International Pharmaceuticals Plc's employee growth, exchange listings and data sources
- Name: Neimeth International Pharmaceuticals Plc
- Ticker: NEIMETH
- Exchange: NGSE
- Founded: 1957
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₦3.343b
- Shares outstanding: 1.90b
- Website: https://www.neimethplc.com.ng
Number of Employees
- Neimeth International Pharmaceuticals Plc
- Plot 16
- Akanni Doherty Layout
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 20:58|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.